HIV-Associated Lymphoma, High-Grade B-Cell Lymphoma, CD4 Count, Diagnostic Challenge, Immune Preservation, Non-Hodgkin ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Entry of viral capsids into the nucleus ...

From daily news and career tips to monthly insights on AI, sustainability, software, and more—pick what matters and get it in your inbox.

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Introduction: The HIV-1 Tat protein is essential for virus replication and spread and is therefore a potential target for anti-HIV therapy. Anti-Tat antibodies have been shown to slow HIV disease ...

DOR/ISL demonstrated non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with virologically suppressed HIV-1 RAHWAY, N.J ...

This fundamental, clearly written, and timely manuscript links the timing of ART with the kinetics of total and intact proviral HIV DNA. The conclusions are interesting and novel, and the importance ...

Abstract: HIV is a major health issue in LMICs, necessitating precise viral load (VL) monitoring for effective management. Antiretroviral therapy (ART) has made HIV manageable, underscoring the need ...